Metabolic nephropathy
Conditions
Interventions
Experimental group (traditional Chinese medicine):Western basic treatment+oral administration of traditional Chinese medicine
Control group (traditional Chinese medicine):Western medicine basic treatment+placebo
Experimental group (external treatment rehabilitation):Traditional Chinese Medicine External Treatment+Rehabilitation Treatment
Control group (external treatment rehabilitation):Conventional Western Medicine Treatment
Western medicinea doctor trained in Western medicine
1.
:COPD.
Conclusion: TCM combined with
Group B ( 40 cases) was treated with tetramethylpyrazine injection 80 ? 120 mg/ d intravenous drip besides conventional therapy
dict.cnki.net
4.
,SAP.
Treatment effectiveness of integrated TCM-WM is better than conventional therapy of west medicine. Now, TCM is become one of important complementary therapies of
Sponsors
Ningbo Municipal Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Western medicine diagnosis meets the diagnostic criteria of diabetes nephropathy/uric acid nephropathy, and GFR >= 30ml/min/1.73m^2; 2. Traditional Chinese medicine syndrome differentiation is consistent with spleen and kidney deficiency, turbidity and stasis resistance syndrome; 3. Age between 18-75 years old; 4. Accompanied by hypertension (with medication to control blood pressure <= 130/80mmHg) or without hypertension; 5. Have been taking Irbesartan tablets continuously for 2 weeks or more; 6. The subject agrees and signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe diseases of important organs, such as moderate to severe liver dysfunction (transaminase levels three times higher than normal), malignant tumors, severe anemia (HB less than 60g/L), and those who have undergone cardiovascular and cerebrovascular stenting in the past three months; 2. Those who are currently taking hormones or immunosuppressants; 3. Individuals who are allergic to known components of the investigational drug or have a severe allergic constitution; 4. Pregnant or lactating women; 5. Existence of neurological and psychiatric disorders; 6. Participated in other clinical trials within the first 3 months of screening, and also participated in other trial projects during this period; 7. Other situations where the researcher judges poor compliance or deems it unsuitable to participate in the trial; 8. After adjusting the antihypertensive medication, the blood pressure is greater than 180/90mmHg or less than 90/60mmHg; Or after clinical treatment, blood potassium levels may exceed 5.5mmol/L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| renal function;Urinary protein/creatinine;Rehabilitation Rating Scale (QOL, MMT, ROM, FIM); | — |
Secondary
| Measure | Time frame |
|---|---|
| glomerular filtration rate;blood electrolyte;liver function;blood fat;blood sugar;Blood routine;Urinalysis;Urinary NAG enzyme;Blood Metabolomics;Urinary Metabolomics; | — |
Countries
China
Contacts
Public ContactGuanghui Zhong
Ningbo Municipal Hospital of Traditional Chinese Medicine
Outcome results
None listed